Tumors exploit immune checkpoint pathways by expressing checkpoint ligands like PD-L1, which bind to checkpoint receptors like PD-1 on T cells. This interaction sends an inhibitory signal to the T cell, preventing it from attacking the tumor cell. This mechanism allows tumor cells to evade immune detection and destruction, facilitating tumor growth and progression.
